Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation

Melanie Demes1,2, Ursula Pession2,3, Jan Jeroch1, Falko Schulze1,2, Katrin Eichler2,4, Daniel Martin2,5, Peter Wild1,2 and Oliver Waidmann2,6,7

1Dr. Senckenbergisches Institut für Pathologie, Universitätsklinikum Frankfurt, Frankfurt 60590, Germany
2Universitäres Centrum für Tumorerkrankungen (UCT), Universitätsklinikum Frankfurt, Frankfurt 60590, Germany
3Klinik für Allgemein- und Viszeralchirurgie, Universitätsklinikum Frankfurt, Frankfurt 60590, Germany
4Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Frankfurt, Frankfurt 60590, Germany
5Klinik für Strahlentherapie und Onkologie, Universitätsklinikum Frankfurt, Frankfurt 60590, Germany
6Medizinische Klinik 1, Schwerpunkte Gastroenterologie und Hepatologie, Universitätsklinikum Frankfurt, Frankfurt 60590, Germany
7Centrum für Hämatologie und Onkologie, Frankfurt 60389, Germany

Correspondence to: Oliver Waidmann, email: oliver.waidmann@kgu.de

Keywords: anal cancer; microsatellite instability; immunotherapy; high-throughput nucleotide sequencing; nivolumab

ABSTRACT

Anal cancer is a rare disease with increasing incidence. In patients with locally recurrent or metastatic disease which cannot be treated with chemoradiotherapy or salvage surgery systemic first-line chemotherapy with carboplatin and paclitaxel is standard of care. For patients who progress after first-line therapy and are still eligible for second-line therapy Programmed cell death protein 1 (PD-1) antibodies are potential therapeutic options. However, prediction of response to immunotherapy is still challenging including anal cancer. We report here to our knowledge the first anal cancer case with microsatellite instability (MSI) due to MLH1 mutation and a deep and ongoing response to Nivolumab treatment. Namely, thorough analysis of the primary tumor as well as metastatic sites by next generation sequencing (NGS) revealed that MSI was formally only found in the metastatic sites but not in the primary tumor. Concomitantly, tumor mutational burden (TMB) was higher in the metastatic site than in the primary tumor. Therefore, we conclude that all anal cancer patients should be tested for MSI and whenever possible molecular analysis should be performed rather from metastatic sites than from the primary tumor.

INTRODUCTION

Anal cancer (AC) is a rare, but rising disease with an annual incidence of less than 2 cases per 100,000 inhabitants [1]. The main risk factor for AC development is HPV infection and most common histological type of anal cancer is squamous cell type [2]. In HIV infected males relatively high numbers of AC cases are found [3]. In patients with earlier stages chemoradiotherapy is the standard of care [4, 5]. With a local failure rate of 15% after chemoradiotherapy, salvage surgery is the only chance of cure in patients with persistent or recurrent AC. Overall distant metastasis occurs in 10–20% of patients [5]. There has not been any standard chemotherapy regimen for decades [5]. Recently, convincing data from a randomized phase 2 trial established the combination Carboplatin/Paclitaxel as new standard of care for first-line palliative chemotherapy [6]. At note, there is only little data on second-line chemotherapy treatment in AC patients [7]. For patients with advanced AC two
prospective clinical trials showed promising activity of the Programmed cell death protein-1 (PD-1) directed monoclonal antibodies Pembrolizumab and Nivolumab, respectively [8, 9]. However, only two HIV infected patients were treated with Nivolumab in the NCI9673 trial with one of the two treated patients showing response to treatment [9]. Altogether, there is little data on PD-1 treatment in HIV infected patients. Recently, a retrospective analysis of HIV infected veterans treated with nivolumab mainly for lung cancer was published [10]. The efficacy of nivolumab was similar to non-infected patients. However, immune-related adverse events were relatively frequent [10], whereas a systemic review did not find new safety signal [11]. Response prediction to PD-1 directed therapy is still challenging and clinically mostly performed by testing for microsatellite instability (MSI) or DNA mismatch repair (MMR) deficiency [12]. We report a case of an HIV infected patient with anal cancer, MSI high status, a high mutation frequency regarding tumor mutational burden (TMB) and an ongoing response to Nivolumab.

RESULTS

A 53 years old HIV infected male patient was diagnosed with AC in September 2015. The patient had been diagnosed with HIV 6 years before, in 2009. At first presentation he was on highly active antiretroviral therapy with Dolutegravir and Emtricitabin/Tenofovir. In initial staging there was no sign for distant metastasis but unilateral inguinal and iliac lymph node enlargement was found corresponding to a clinical stage, cT2 cN2 G2. He underwent definitive chemoradiotherapy of the tumor, the involved and elective lymph nodes with a total dose of 59.4 Gy. The patient received fluorouracil 800 mg/m² per day on days 1–5 (week 1) and days 29–33 (week 5) by continuous 24 h intravenous infusion with radiotherapy, and 10 mg/m² of mitomycin as an intravenous bolus on day 1 (week 1) and day 29 (week 5). In May 2016, 17 months after the initial diagnosis, the patient presented with local recurrence. He underwent salvage surgery with abdominoperineal resection (APR) in June 2016. Pathological examination of the resected tissue showed R1 resection (rpT1 ryN0 (0/13) L0 V0 Pn1, R1). Three months later the patient reported a node in the right groin, which was resected and histopathology revealed metastasis of AC. Additional therapy was not performed. Four months later, in February 2017, restaging with computed tomography scans found multiple lymph node metastases in the retroperitoneum up to the left supravacular area. Excision of a left supraclavicular lymph node showed metastasis of the AC. Immunohistochemistry found 2% of the tumor cells expressing PD-L1. (Figure 1). First-line chemotherapy with Cisplatin 60 mg/m² (d1) and Capecitabine 2500 mg/m² (d1-14) every three weeks was started in March 2017. First staging after three months showed stable disease; therefore chemotherapy was continued. After additional three months of therapy, in September 2017 progression of lymph node metastasis was detected. Chemotherapy was escalated by adding Docetaxel 75 mg/m² (d1) to the chemotherapy regimen with Cisplatin 60 mg/m² (d1) and Capecitabine 2500 mg/m² (d1-14) every three weeks. Next staging in January 2018 showed again progressive disease. Given the promising data from the NCI9673 trial [9], treatment with Nivolumab 3 mg/kg every 2 weeks was initiated in February 2018. Staging with contrast-enhanced computed tomography after three months in May 2018 showed regression of lymph node metastasis (Figure 2). Treatment was continued and next staging in August 2018 revealed partial response, and complete response in February 2019. Treatment was continued until February 2020 and stopped thereafter with ongoing complete response in March 2020 (Figure 2). Patient showed ongoing response to therapy up to February 2021. During chemotherapy with Cisplatin, Capecitabine and Docetaxel CD4 counts decreased to 87/μl. After the end of chemotherapy and after initiation of immunotherapy (IT) CD4 cells raised to 171/μl and lately to 264/μl. HIV 1-RNA has not been detectable during all treatment courses.

DISCUSSION

AC is a rare disease with increasing rates of new diagnoses [1]. Especially male HIV infected patients have a relatively high risk for AC development [3]. The predominant number of AC in patients with HIV infection are HPV related [3]. Cancers associated with viral infections often show an inflammatory microenvironment [13]. In patients with such virus-associated cancers higher response rates to IT are found compared to the response rates in patients with cancers not associated with viral infections [14]. The potential of IT to induce responses and disease stabilization in AC patients was shown in the NCI9673 trial [9]. However, only 2 of 37 treated patients were HIV positive and only one of the two patients showed a response [9]. Overall, patients with response had higher PD-L1 levels in the tumors and higher concentration of CD8 T cells in the surrounding tissue [9]. In our patient strong p16 expression in the tumor cells was seen fitting to HPV infection. Additionally, PD-L1 expression was also found in the tumor cells, although in a relative low proportion of 2%. In the KEYNOTE-028 study, patients with PD-L1 expression of ≥1% including both neoplastic cells and contiguous mononuclear inflammatory cells, received Pembrolizumab 10mg/kg body weight every two weeks for up to two years [8]. The response rate was comparable with 17%. However, HIV infected patients were excluded from the trial (NCT02054806). Generally, HIV infection is associated with increased expression of PD1 on T-cells leading to impairment of
T cell activation [15]. PD-L1 blockade modulates and restores cytokine production and leads to proliferation of HIV specific CD4 T-cells [16]. In our case we observed a rising count of CD4 positive cells by persistent negative HIV 1-RNA status during Nivolumab therapy (data not shown). Safety and efficacy of PD-1 treatment in real life has recently been reported in a French cohort of HIV infected patients [17].

Prediction of response to IT is still challenging. Microsatellite instability (MSI) and to a somewhat lesser extent TMB are predictors of response to PD1/PD-L1 directed therapy [18]. Namely, MSI is rare but high TMB is frequently found in AC [18]. To our knowledge no patient case with HIV associated AC, MSI and ongoing response has been published. The mismatch repair mechanism corrects mismatches generated during DNA replication and recombination and therefore maintains genomic stability. Mismatch repair (MMR) proteins/genes may show a loss of function characterizing a MMR-deficient (MMR-D) tumor. In this particular case MLH1 and PMS2 expression was lost at all tumor sites. These specific proteins were still expressed in the tumor surrounding tissue indicating an somatic event. We also found the mutation of MLH1 in the primary tumor as

Figure 1: Histochemistry and immunohistochemistry of tumor tissue of primary cancer and lymph node metastasis.
Slides from formalin fixed paraffin embedded tissue samples form primary tumor and supraclavicular metastasis were stained for Hematoxylin-eosin, p16 and PD-L1.
well as in the metastatic sites. The allele frequency of detected alterations rather indicates an somatic event, too. Loss of PMS2 expression can be also caused by MLH1 mutation or MLH1 promotor hypermethylation. Generally MLH1 and PMS2 form heterodimers that may repair damages in the DNA. According to some studies, human immunodeficiency virus infection was associated with a microsatellite unstable tumor. Thus a study reveals a shift to MLH1 loss in gastric cancer with high HIV prevalence [19–21].

PIK3CA mutations were detected in the metastatic and primary tumor. Oncogenic PIK3CA mutations contribute to tumorigenesis by activating AKT signaling to decrease apoptosis and increase tumor invasion. Distinct studies have reported that PIK3CA mutation is more commonly mutated in the MSI molecular subgroup. According to the literature PIK3CA mutations has an independent prognostic value for patients who underwent recurrence. This subgroup may potentially benefit from adjuvant treatment and targeted therapies with PI3K/Akt/mTor inhibitors [22–24].

No mutational event was detected in the genes RAS and BRAF.

A high concordance rate between primary cancer and metastatic disease concerning driver mutations such as RAS or BRAF but also MSI has been reported from colorectal cancer [25–27]. A clinically relevant proportion of unstable MSI sites and also a high TMB were only found in the metastatic sites. As TMB is predictor for tumor response in different cancer entities including lung cancer and AC [28–30]. Response prediction to PD-1 directed therapy is still challenging and clinically mostly performed by testing for microsatellite instability (MSI) or DNA mismatch repair (MMR) deficiency [12].

Figure 2: Contrast enhanced computed tomography of the chest and abdomen at beginning, during and at the end of nivolumab treatment. Representative lymph node metastases are shown before, during at end of treatment. Arrows show the metastatic sites before start of treatment.
This case report represents an HIV infected patient with anal cancer, MSI high status, a high mutation frequency regarding tumor mutational burden (TMB) and an ongoing response to Nivolumab. According to our results, we propose to assess mutational status in tissue from metastasis rather than from the primary site when additional molecular analyses are performed for treatment decisions.

MATERIALS AND METHODS

Immunohistochemical staining of the PD-L1 (clone ZR3), p16 (clone INK4A) as well as mismatch repair (MMR) proteins MLH1 (clone BS29), MSH2 (clone G219-1129), MSH6 (clone SP93) and PMS2 (clone EP51) was done using the OMNIS (Agilent) automated advanced staining technique. To determine the tumor area of interest and corresponding tumor cell content the tissue samples were stained with hematoxylin/eosin by the Sakura Tissue-Tek Prisma® Plus and Tissue-Tek Film®. An experienced pathologist assessed the slides.

For molecular characterization of a 523-gene panel (TSO500, Illumina, San Diego, California, USA), paraffin-embedded tissue sections were macrodissected from tumor for DNA and RNA extraction. The purification of DNA and RNA from the formalin-fixed paraffin embedded (FFPE) tissue samples was performed using the QIAamp FFPE Tissue Kit (QIAGEN) and the Maxwell® RSC FFPE DNA Kit (Promega Corporation, Madison, Wisconsin, USA), respectively. Further preparation and the instrument run were performed according to manufacturer’s protocol. The concentration of DNA and RNA was measured with the Qubit 4 Fluorometer (Invitrogen, Thermo Fisher, Waltham, Massachusetts, USA). For the library preparation the hybrid capture-based TSO 500 library preparation kit (Illumina) were finally sequenced using V2 sequencing reagent kits on a NextSeq550 platform (Illumina) according to manufacturer recommendations.

Data analysis was performed using the analysis BaseSpace TSO 500 Assessment App (Illumina). Molecular Health was used as interpretation software.

A variant allele frequency (VAF) >5% and a total read depth of >50X were filtered for analysis. For MSI, 130 MSI loci sites were algorithmic analyzed by calculating a quantitative score. The performance of TMB detection is set by analyzing SNVs and indels in the coding regions reading somatic alterations. The TMB score is defined as the number of eligible somatic mutations per Mb (targeted region defined as high confidence regions with >50× coverage).

Histological and molecular analysis

FFPE material was accessible from the resected primary tumor, inguinal metastasis as well as from a supraclavicular lymph node metastasis. Staining for H&E, p16 and PD-L1 of different tumors was performed (Figure 1). p16 expression was detected at the primary site and the metastasis and PD-L1 expression was found in 2% of the tumor cells indicating a TPS Score of 2%. As the patient showed impressive response to Nivolumab we performed additional staining for MMR proteins. At both analyzed tumor probes loss of MLH1 and PMS2 was found, but MLH1 and PMS2 were still expressed in tumor surrounding tissue (Figure 3). However, only the two biopsies of the metastatic site but not the tissue from the primary cancer showed more than 20% of unstable MSI sites (Table 1A). For further work-up NGS analysis of three tumor site was performed. MLH1 mutation

---

Table 1A: Microsatellite instability (MSI), cutoff (percent of unstable MSI sites) = 20%

|                  | Primary tumor | Supraclavicular metastasis | Inguinal metastasis |
|------------------|---------------|----------------------------|---------------------|
| Unstable MSI sites | 155           | 117                        | 115                 |
| Unstable MSI sites (total) | 17            | 29                         | 25                  |
| Percent unstable MSI sites | 14.78        | 24.79                      | 21.74               |
| MSI status       | stable        | unstable                   | unstable            |

Table 1B: Tumor mutational burden (TMB), coding target region size 1.31 MB

|                  | Primary tumor | Supraclavicular metastasis | Inguinal metastasis |
|------------------|---------------|----------------------------|---------------------|
| Non-synonymous SNVs | 15 (11.43 Mut/Mb) | 29 (22.10 Mut/Mb)          | 35 (26.67 Mut/Mb)   |
| synonymous SNVs   | 4 (3.05 Mut/Mb) | 13 (9.91 Mut/Mb)           | 13 (9.91 Mut/Mb)    |
| Deletions, insertions, indels | 4 (3.05 Mut/Mb) | 9 (6.86 Mut/Mb)            | 12 (9.15 Mut/Mb)    |
| TMB based on selected variant types (Mut/Mb) | 17.53 (TMB-L/TMB-H) | 38.87 (TMB-H)              | 45.73 (TMB-H)       |

Defined TMB-L threshold TMB (Mut/Mb) < 5
Defined TMB-H threshold TMB (Mut/Mb) > 20
(c.588dupA) could be detected with an allelic frequency (AF) ranging from 40% to 50% at all three tumor sites. Additionally, all three tumor sites showed a PIK3CA mutation (p.E545K) (AF ranging from 45% to 48%). It is known, that activating mutations in PIK3CA drive anal carcinogenesis and that the PI3K/mTOR pathway is a relevant target for therapeutic intervention. TMB was calculated from the analysis from the different sites.

**Figure 3: Expression of mismatch repair proteins in primary tumor and supraclavicular metastasis.** Slides from formalin fixed paraffin embedded tissue samples from primary tumor and supraclavicular metastasis were stained for Hematoxylin-eosin, and the mismatch repair proteins MLH1, PMS2, MSH2, and MSH6.
Namely only the metastatic sites showed a high TMB with the defined TMB-H threshold of > 20 mutations per megabase (Table 1B).

**Patient update**

Given the promising data from the NCI9673 trial [9], treatment with Nivolumab 3 mg/kg every 2 weeks was initiated in February 2018. Staging with contrast-enhanced computed tomography after three months in May 2018 showed regression of lymph node metastasis (Figure 2). Treatment was continued and next staging in August 2018 revealed partial response, and complete response in February 2019. Treatment was continued until February 2020 and stopped thereafter with ongoing complete response in March 2020 (Figure 2). Patient showed ongoing response to therapy up to February 2021.

During chemotherapy with Cisplatin, Capecitabine and Docetaxel CD4 counts decreased to 87/μl. After the end of chemotherapy and after initiation of immunotherapy (IT) CD4 cells raised to 171/μl and lately to 264/μl. HIV 1-RNA has not been detectable during all treatment courses.

**Data availability**

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Author contributions**

Melanie Demes conceived, designed and contributed to the draft of the paper. Ursula Pession collected data and contributed to the draft of the paper. Jan Jeroch performed analyses and contributed to the draft of the paper. Falko Schulze performed analyses. Katrin Eichler contributed data. Daniel Martin analyzed data and contributed to the draft of the paper. Oliver Waidmann collected data, performed analyses and wrote the paper. All authors approved the final version of the manuscript.

**CONFLICTS OF INTEREST**

Ursula Pession, Jan Jeroch, Falko Schulze, Katrin Eichler, and Daniel Martin have nothing to declare.

Melanie Demes received consulting/lecture fees from Amgen, AstraZeneca, Bayer, Biocartis, Diaceutics, Roche, Sophia Genetics.

Peter Wild received consulting/lecture fees from AstraZeneca, Janssen, Roche, Astellas, Bayer, Bristol-Myers Squibb, Janssen, Novartis, Thermo Fisher Scientific, MSD, Qiagen, Molecular Health, Sophia Genetics.

Oliver Waidmann received consulting/lecture fees from Amgen, AstraZeneca, Bayer, BMS, Celgene, Eisai, Falk, Incyte, Ipsen, Merck, MSD, Novartis, Roche, Servier, and Shire.

**Ethical statement and consent**

Written informed consent was obtained from the patient for publication of this manuscript and any accompanying data and images. Translational research for biomaterial of cancer patients was approved of the Ethics Committee of the Goethe University Frankfurt (file number: 4/09).

**REFERENCES**

1. Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Jemal A. International trends in anal cancer incidence rates. Int J Epidemiol. 2017; 46:924–38. [PubMed]

2. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009; 124:1626–36. [PubMed]

3. Shiels MS, Pfeiffer RM, Chaturvedi AK, Kreimer AR, Engels EA. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst. 2012; 104:1591–98. [PubMed]

4. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997; 15:2040–49. [PubMed]

5. Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D. Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 (Suppl 3); 25:iii10–20. [PubMed]

6. Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, et al. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020; 38:2510–18. [PubMed]

7. Sclafani F, Rao S. Systemic Therapies for Advanced Squamous Cell Anal Cancer. Curr Oncol Rep. 2018; 20:53. [PubMed]
8. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017; 28:1036–41. [https://doi.org/10.1093/annonc/mdx029] [PubMed]

9. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18:446–53. [https://doi.org/10.1016/S1470-2045(17)30104-3] [PubMed]

10. Chang E, Sabichi AL, Kramer JR, Hartman C, Royse KE, White DL, Patel NR, Richardson P, Yellapragada SV, Garcia JM, Chiao EY. Nivolumab Treatment for Cancers in the HIV-infected Population. J Immunother. 2018; 41:379–83. [https://doi.org/10.1097/CJI.0000000000000240] [PubMed]

11. Cook MR, Kim C. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol. 2019; 5:1049–54. [https://doi.org/10.1001/jamaoncol.2018.6737] [PubMed]

12. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki D, Donehower RC, Zhou Z, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372:2509–20. [https://doi.org/10.1056/NEJMoa1500596] [PubMed]

13. Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. Clin Cancer Res. 2016; 22:2261–70. [https://doi.org/10.1158/1078-0432.CCR-15-2834] [PubMed]

14. Outh-Gauer S, Alt M, Le Tourneau C, Augustin J, Broudin C, Gasne C, Denize T, Mirghani H, Fabre E, Ménard M, Scotte F, Tartour E, Badoual C. Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. Cancer Treat Rev. 2018; 65:54–64. [https://doi.org/10.1016/j.ctrv.2018.02.008] [PubMed]

15. Grabmeier-Pfistershammer K, Steinberger P, Rieger A, Leitner J, Kohrgruber N. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J Acquir Immune Defic Syndr. 2011; 56:118–24. [https://doi.org/10.1097/QAD.0b013e3181fba89f] [PubMed]

16. Porichis F, Kwon DS, Zuñkosky J, Tighe DP, McMullen A, Brockman MA, Pavlik DF, Rodriguez-Garcia M, Pereyra F, Freeman GA, Kavanagh DG, Kaufmann DE. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011; 118:965–74. [https://doi.org/10.1182/blood-2010-12-328070] [PubMed]

17. Spano JP, Veyri M, Gobert A, Guihot A, Perré P, Kerjouan M, Brosseau S, Cloarec N, Montaudie H, Helissey C, Flamant T, Gounant V, Lavolé A, et al. Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience. AIDS. 2019; 33:F13–19. [https://doi.org/10.1097/QAD.0000000000002298] [PubMed]

18. Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xi J, Korn WM, Weinberg BA, Hwang J, Shields AF, Marshall JL, Philip PA, Lenz HJ. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Mol Cancer Res. 2018; 16:805–12. [https://doi.org/10.1158/1541-7786.MCR-17-0735] [PubMed]

19. Wang T, Stadler ZK, Zhang L, Weiser MR, Basturk O, Hechtman JF, Vakiani E, Saltz LB, Klimstra DS, Shia J. Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations. Fam Cancer. 2018; 17:225–28. [https://doi.org/10.1007/s10689-017-0031-9] [PubMed]

20. Kosinski J, Hinrichsen I, Bujnicki JM, Friedhoff P, Plotz G. Identification of Lynch syndrome mutations in the MLH1-PM52 interface that disturb dimerization and mismatch repair. Hum Mutat. 2010; 31:975–82. [https://doi.org/10.1002/humu.21301] [PubMed]

21. Kayamba V, Butt J, Waterboer T, Besa E, Choudhry N, Hamasuku A, Julius P, Heimberger DC, Atadzhanov M, Kelly P. Molecular profiling of gastric cancer in a population with high HIV prevalence reveals a shift to MLH1 loss but not the EBV subtype. Cancer Med. 2020; 9:3445–54. [https://doi.org/10.1002/cam4.3001] [PubMed]

22. Whitehall VL, Rickman C, Bond CE, Ramsnes I, Greco SA, Umapathy A, McKeone D, Faleiro RJ, Buttenshaw RL, Worthley DL, Nayler S, Zhao ZZ, Montgomery GW, et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer. 2012; 131:813–20. [https://doi.org/10.1002/ijc.26440] [PubMed]

23. Li W, Qiu T, Dong L, Zhang F, Guo L, Ying J. Prevalence and characteristics of PIK3CA mutation in mismatch repair-deficient colorectal cancer. J Cancer. 2020; 11:3827–33. [https://doi.org/10.7150/jca.37437] [PubMed]

24. Jin J, Shi Y, Zhang S, Yang S. PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis. Acta Oncol. 2020; 59:66–74. [https://doi.org/10.1080/02841810.2016.1664764] [PubMed]

25. Fujiyoshi K, Yamamoto G, Takahashi A, Ariy Y, Yamada M, Kubota M, Yamaguchi K, Akagi Y, Nishimura Y, Sakamoto H, Akagi K. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep. 2017; 38:920–26. [https://doi.org/10.3892/or.2016.5323] [PubMed]

26. He WZ, Hu WM, Wang F, Rong YM, Yang L, Xie QK, Yang YZ, Jiang C, Qiu HJ, Lu JB, Zhang B, Ding PR,...
Xia XJ, et al. Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer. J Natl Compr Canc Netw. 2019; 17:1174–83. https://doi.org/10.6004/jnccn.2019.7308. [PubMed]

27. Wang Z, Tang X, Wu X, Yang M, Wang D. Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study. Biosci Rep. 2019; 39:BSR20190730. https://doi.org/10.1042/BSR20190730. [PubMed]

28. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, et al, and CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376:2415–26. https://doi.org/10.1056/NEJMoai1613493. [PubMed]

29. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21:1353–65. https://doi.org/10.1016/S1470-2045(20)30445-9. [PubMed]

30. Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, Amin-Mansour A, Miao D, Damish A, Chin J, Ott PA, Fuchs CS, Martin NE, et al. Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clin Cancer Res. 2017; 23:3214–22. https://doi.org/10.1158/1078-0432.CCR-16-2017. [PubMed]